Literature DB >> 17133421

Imatinib mesylate responsiveness in aggressive systemic mastocytosis: novel association with a platelet derived growth factor receptor beta mutation.

Bakul I Dalal1, Douglas E Horsman, Hélène Bruyèrè, Donna L Forrest.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17133421     DOI： 10.1002/ajh.20833

Source DB:  PubMed          Journal:  Am J Hematol        ISSN： 0361-8609            Impact factor:   10.047


× No keyword cloud information.
  3 in total

1.  Myeloid tumors accompanying systemic mastocytosis, basophilia, and abnormal platelet-derived growth factor receptor β: A case report.

Authors:  Yanfen Li; Yu Jing; Hua Wan; Daihong Liu
Journal:  Medicine (Baltimore)       Date:  2021-02-26       Impact factor: 1.817

Review 2.  Pharmacology and rationale for imatinib in the treatment of scleroderma.

Authors:  Pia Moinzadeh; Nicolas Hunzelmann; Thomas Krieg
Journal:  J Exp Pharmacol       Date:  2013-04-04

3.  Imatinib in systemic mastocytosis: a phase IV clinical trial in patients lacking exon 17 KIT mutations and review of the literature.

Authors:  Iván Alvarez-Twose; Almudena Matito; José Mário Morgado; Laura Sánchez-Muñoz; María Jara-Acevedo; Andrés García-Montero; Andrea Mayado; Carolina Caldas; Cristina Teodósio; Javier Ignacio Muñoz-González; Manuela Mollejo; Luis Escribano; Alberto Orfao
Journal:  Oncotarget       Date:  2016-07-19
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.